Herrmann, Sebastian https://orcid.org/0009-0002-2138-5176
Graefe, Stephanie
Christopeit, Maximilian https://orcid.org/0000-0003-4627-0412
Sonnemann, Piet https://orcid.org/0000-0003-2488-0316
Hattenhauer, Tessa https://orcid.org/0009-0001-3320-8815
Mispelbaum, Rebekka https://orcid.org/0009-0000-6891-8705
Monin, Malte B. https://orcid.org/0000-0002-8794-3612
Orth, Hans Martin https://orcid.org/0000-0003-3053-6730
Flasshove, Charlotte
Gruell, Henning https://orcid.org/0000-0002-0725-7138
Klein, Florian https://orcid.org/0000-0002-7082-0317
Klein, Uwe https://orcid.org/0000-0002-7516-4347
Lehmann, Clara https://orcid.org/0000-0002-7042-1578
Naendrup, Jan-Hendrik https://orcid.org/0000-0002-6420-7938
Stemler, Jannik https://orcid.org/0000-0001-9152-2469
Salmanton-Garcia, Jon https://orcid.org/0000-0002-6766-8297
Markus, Theresa
Cornely, Oliver A. https://orcid.org/0000-0001-9599-3137
Mellinghoff, Sibylle C. https://orcid.org/0000-0003-3928-2503
Funding for this research was provided by:
Universitätsklinikum Köln
Article History
Received: 28 September 2024
Accepted: 2 December 2024
First Online: 17 December 2024
Declarations
:
: JS reports grants or contracts from the Federal Ministry of Education and Research Medical Faculty of the University of Cologne, from Basilea and Noscendo. Payments were made to his insti-tution. He received Consulting fees by Gilead, Mundipharma, Alvea Vax and Micron Research, payments or honoraria for presentations, speakers bureaus, manuscript writing or educational events by AbbVie, Hikma, Gilead, Pfizer. Receipt of equipment, materials, drugs, medical writing, gifts or other services payments made to the institution by Basilea.RM received travel support by Takeda and Janssen. She is part of the advisory board of Janssen.JSG is part of the Advisory board of Pfizer, not involved in the work presented, he received Speaker honoraria by AstraZeneca, Gilead Sciences, Menarini and Pfizer, not involved in the work presented.MBM received travel expenses and honoraria for lectures and/or consultancies from Abbvie, AstraZeneca, Gilead Sciences, Novavax, Pfizer, Takeda, ViiV Healthcare and Virology Edu-cation. FK declares that Patent applications on antibodies against viral pathogens have been filed by the University of Cologne, listing FK as inventor.OAC reports grants or contracts from BMBF, Cidara, DZIF, EU-DG RTD, F2G, Gilead, MedPace, MSD, Mundipharma, Octapharma, Pfizer, Scynexis; Consulting fees from Abbvie, AiCuris, Basilea, Biocon, Boston Strategic Partners, Cidara, Seqirus, Gilead, GSK, IQVIA, Janssen, Matinas, Med-Pace, Menarini, Molecular Partners, MSG-ERC, Mundipharma, Noxxon, Octapharma, Pardes, Part-ner Therapeutics, Pfizer, PSI, Scynexis, Seres, Shionogi, The Prime Meridian Group; Speaker and lecture honoraria from Abbott, Abbvie, Akademie für Infektionsmedizin, Al-Jazeera Pharmaceuti-cals/Hikma, amedes, AstraZeneca, Deutscher Ärzteverlag, Gilead, GSK, Grupo Biotoscana/United Medical/Knight, Ipsen Pharma, Medscape/WebMD, MedUpdate, MSD, Moderna, Mundipharma, Noscendo, Paul-Martini-Stiftung, Pfizer, Sandoz, Seqirus, Shionogi, streamedup!, Touch Inde-pendent, Vitis; Payment for expert testimony Cidara; Participation on a DRC, DSMB, Advisory Board for Cidara, IQVIA, Janssen, MedPace, PSI, Pulmocide, Vedanta Biosciences.SCM received research grants by DZIF (Deutsches Zentrum für Infektionsforschung) and the Uni-versity Hospital of Cologne. She received honoraria as a consultant by Octapharma and as a speaker by Pfizer. None of these involved in the work presented.SH, MC, PS, TH, HMO, CF, HG, UK, CL, JHN, TM declare no conflict of interests.